156 related articles for article (PubMed ID: 24427363)
21. Primary penile lymphoma: the use of PET-CT for accurate staging and response monitoring.
Karunanithi S; Sharma P; Naswa N; Soundararajan R; Mohapatra T; Malhotra A; Bal C; Kumar R
Diagn Interv Radiol; 2013; 19(2):130-3. PubMed ID: 23448700
[TBL] [Abstract][Full Text] [Related]
22. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
23. Imaging-guided biopsy of (18)F-FDG-avid extrapulmonary lesions: do lesion location and morphologic features on CT affect the positive predictive value for malignancy?
Nguyen ML; Gervais DA; Blake MA; Mueller PR; Sahani DV; Hahn PF; Uppot RN
AJR Am J Roentgenol; 2013 Aug; 201(2):433-8. PubMed ID: 23883226
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDG PET/CT demonstrating primary bone lymphoma of the extremities mimicking an inflammatory peripheral arthropathy.
Tachibana A; Robinson RJ; Patel CN
Clin Nucl Med; 2015 Feb; 40(2):169-71. PubMed ID: 25140543
[TBL] [Abstract][Full Text] [Related]
25. Systematic Review on the Additional Value of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging Follicular Lymphoma.
Adams HJ; Nievelstein RA; Kwee TC
J Comput Assist Tomogr; 2017 Jan; 41(1):98-103. PubMed ID: 27560022
[TBL] [Abstract][Full Text] [Related]
26. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
27. (18) F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma.
Ujjani CS; Hill EM; Wang H; Nassif S; Esposito G; Ozdemirli M; Cordova C; Cheson BD
Br J Haematol; 2016 Aug; 174(3):410-6. PubMed ID: 27098364
[TBL] [Abstract][Full Text] [Related]
28. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.
Brahmi M; Thiesse P; Ranchere D; Mognetti T; Pinson S; Renard C; Decouvelaere AV; Blay JY; Combemale P
PLoS One; 2015; 10(10):e0138386. PubMed ID: 26445379
[TBL] [Abstract][Full Text] [Related]
30. FDG PET/CT Imaging of an Isolated Recurrence in the Eyelid of a Patient With Follicular Lymphoma.
Ekmekcioglu O; Vatankulu B; Akyel R; Ozbayrak M; Sonmezoglu K
Clin Nucl Med; 2015 Nov; 40(11):871-2. PubMed ID: 26284766
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.
Ulaner GA; Goldman DA; Sauter CS; Migliacci J; Lilienstein J; Gönen M; Schöder H; Moskowitz CH; Zelenetz AD
Radiology; 2015 Nov; 277(2):518-26. PubMed ID: 26035588
[TBL] [Abstract][Full Text] [Related]
32. Bone involvement in patients with lymphoma: the role of FDG-PET/CT.
Schaefer NG; Strobel K; Taverna C; Hany TF
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):60-7. PubMed ID: 17021808
[TBL] [Abstract][Full Text] [Related]
33. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
34. Histological transformation of follicular lymphoma after treatment: a case evaluated with PET/CT.
Mena LM; Setoain X; Abrisqueta P; Rodríguez S; López-Guillermo A; Fuster D; Lafuente S; Fuertes S; Rubí S; Pons F
Clin Nucl Med; 2009 Nov; 34(11):793-4. PubMed ID: 19851178
[No Abstract] [Full Text] [Related]
35. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
[TBL] [Abstract][Full Text] [Related]
36. Fluorothymidine PET/CT in neurolymphomatosis.
Biswal CK; Mittal BR; Shukla J; Vatsa R; Bhattacharya A; Prabhakar S
Clin Nucl Med; 2015 May; 40(5):e290-2. PubMed ID: 25546221
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Importance of Bone Marrow Uptake on Baseline
Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
[TBL] [Abstract][Full Text] [Related]
38. [Diagnostic value of FDG-PET in the detection of bone marrow involvement in patients with diffuse large B-cell lymphoma].
Zhang X; Fan W; Lin XP
Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):832-5. PubMed ID: 19176040
[TBL] [Abstract][Full Text] [Related]
39. CT and
Altinmakas E; Üçışık-Keser FE; Medeiros LJ; Ng CS
Acad Radiol; 2019 Jun; 26(6):e108-e114. PubMed ID: 30076085
[TBL] [Abstract][Full Text] [Related]
40. Non-Hodgkin lymphoma dominated by multiple organ extranodal disease revealed on FDG PET/CT.
Bai X; Codreanu I; Kaplan SL; Servaes S; Zhuang H
Clin Nucl Med; 2015 Apr; 40(4):360-3. PubMed ID: 25608171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
